GeoVax Labs, Inc. New (GOVX)

Price$1.65

Value ScoreB

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-91.87%

Price vs S&P 500 (4W)-1.19%

VGM Score36.30

Market Capitalization$5.73M

All Metrics

Book Value / Share (Quarterly)$0.18

P/TBV (Annual)3.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)212.58%

Cash Flow / Share (Quarterly)$-7.23

Price vs S&P 500 (YTD)-69.61%

Gross Margin (TTM)-31.76%

Net Profit Margin (TTM)-403.80%

EPS (TTM)$-21.69

10-Day Avg Trading Volume6.33M

EPS Excl Extra (TTM)$-21.69

Revenue Growth (5Y)6.42%

EPS (Annual)$-22.40

ROI (Annual)-561.15%

Gross Margin (Annual)25.00%

Net Profit Margin (5Y Avg)-4735.50%

Cash / Share (Quarterly)$0.45

ROA (Last FY)-338.46%

Revenue Growth TTM (YoY)-84.76%

EBITD / Share (TTM)$-16.60

ROE (5Y Avg)-397.04%

Operating Margin (TTM)-407.34%

Cash Flow / Share (Annual)$-13.17

P/B Ratio11.61x

P/B Ratio (Quarterly)6.21x

Net Income / Employee (Annual)$-1,129,700

EV / Revenue (TTM)0.73x

Net Interest Coverage (TTM)-19.93x

ROA (TTM)-399.31%

EPS Incl Extra (Annual)$-22.40

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)0.56x

3-Month Avg Trading Volume3.45M

52-Week Price Return-93.94%

Revenue / Employee (TTM)$44,900

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)2.30x

Asset Turnover (Annual)0.39x

52-Week High$34.75

Operating Margin (5Y Avg)-4738.15%

EPS Excl Extra (Annual)$-22.40

CapEx CAGR (5Y)-29.34%

Tangible BV CAGR (5Y)-20.70%

26-Week Price Return-83.95%

Quick Ratio (Annual)1.59x

13-Week Price Return-5.17%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.06x

Enterprise Value$4.46M

Revenue / Share Growth (5Y)-33.36%

Asset Turnover (TTM)0.69x

Book Value / Share Growth (5Y)-43.21%

Revenue / Employee (Annual)$131,000

Inventory Turnover (Annual)5.36x

Pretax Margin (Annual)-862.33%

Cash / Share (Annual)$1.78

3-Month Return Std Dev206.95%

Gross Margin (5Y Avg)-920.72%

Net Income / Employee (TTM)$-1,124,700

ROE (Last FY)-561.15%

Net Interest Coverage (Annual)-2781.44x

EPS Basic Excl Extra (Annual)$-22.40

P/FCF (TTM)14.03x

Receivables Turnover (TTM)7.55x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-21.69

Receivables Turnover (Annual)7.55x

ROI (TTM)-709.51%

P/S Ratio (TTM)0.93x

Pretax Margin (5Y Avg)-4735.50%

Revenue / Share (Annual)$2.60

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-118.31%

Year-to-Date Return-61.45%

5-Day Price Return-25.34%

EPS Normalized (Annual)$-22.40

ROA (5Y Avg)-225.35%

Net Profit Margin (Annual)-862.33%

Month-to-Date Return-19.90%

Cash Flow / Share (TTM)$-0.90

EBITD / Share (Annual)$-22.51

Operating Margin (Annual)-869.33%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-397.04%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-21.69

P/TBV (Quarterly)3.90x

P/B Ratio (Annual)1.34x

Inventory Turnover (TTM)5.82x

Pretax Margin (TTM)-403.80%

Book Value / Share (Annual)$2.21

Price vs S&P 500 (13W)-13.43%

Beta3.73x

P/FCF (Annual)35.82x

Revenue / Share (TTM)$0.42

ROE (TTM)-709.51%

52-Week Low$0.96

vGradeB

gGradeD

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q4 25-0.01est. -6.29

Q1 26-2.62est. -4.51

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
GOVXGeoVax Labs, Inc. New	B	D	F	$1.65
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors using proprietary platforms. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine in human trials, complemented by candidates targeting Monkeypox, hemorrhagic fevers, Zika, and head and neck cancer. The company's approach combines preventive vaccines and gene-directed immunotherapies across a diversified pipeline.